Rontalizumab
Rontalizumab
Rontalizumab (pronunciation: ron-ta-li-zu-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It was developed by Genentech, a member of the Roche Group.
Etymology
The name "Rontalizumab" is derived from the standard nomenclature for monoclonal antibodies. The suffix "-mab" indicates it is a monoclonal antibody, while the prefix "Rontaliz-" is a unique identifier.
Mechanism of Action
Rontalizumab works by inhibiting the interferon alpha (IFN-α), a protein that plays a crucial role in the immune response. By blocking IFN-α, Rontalizumab can help reduce the symptoms of autoimmune diseases.
Clinical Trials
Rontalizumab has undergone several clinical trials for conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). However, the results have been mixed, and the drug is not currently approved for use in any country.
Related Terms
- Monoclonal antibody
- Autoimmune disease
- Interferon alpha
- Systemic lupus erythematosus
- Rheumatoid arthritis
External links
- Medical encyclopedia article on Rontalizumab
- Wikipedia's article - Rontalizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski